IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.
Location: United States, California, South San Francisco
Employees: 1-10
Total raised: $65M
Investors 2
| Date | Name | Website |
| - | AllerFund | allerfund.... |
| 19.04.2022 | Global Bra... | globalbrai... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.02.2023 | Series B | $40M | Khosla Ven... |
| 27.07.2021 | - | $25M | - |
Mentions in press and media 7
| Date | Title | Description |
| 07.02.2023 | IgGenix Holds First Close of $40M Series B Financing | IgGenix, a South San Francisco, CA-based pre-clinical biotechnology company, held the first close of its $40M Series B funding. The round was led by Alexandria Venture Investments with participation from Eli Lilly and Company, as well as ex... |
| 06.02.2023 | IgGenix Announces First Close of $40M Series B | SOUTH SAN FRANCISCO, CA, IgGenix, Inc., a pre-clinical biotechnology company, announced its first close on a $40M Series B financing. >> Click here for more funding data on IgGenix >> To export IgGenix funding data to PDF an... |
| 27.07.2021 | IgGenix Announces $25M in Series A1 Funding | IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that it has raised $25 million in an oversubscribed Series A1 financing. Khosla Ventures, which participated in IgG... |
| 27.07.2021 | IgGenix Raises $25M in Series A1 Funding | IgGenix, Inc., a South San Francisco, CA-based biotechnology company focused on addressing allergic disease, raised $25m in Series A1 financing. Khosla Ventures, which participated in IgGenix’s Series A funding in 2020, co-led the round alo... |
| 04.08.2020 | IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade | A little over six months after the FDA approved the first treatment for peanut allergies, a new biotech has emerged hoping to break through in a field that’s seen virtually no innovation. IgGenix came out of stealth mode Tuesd... |
| - | IgGenix Raises $40 Million To Address Allergic Diseases | IgGenix recently announced it raised $40 million in Series B funding. These are the details. IgGenix – a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic disease – announced its first close on ... |
| - | IgGenix | “IgGenix” |